NanoViricides Inc.
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies developed for the treatment of COVID infection, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments. It also offers NV-387 Solution for injection, infusion, and inhalation to treat severe cases that are not hospitalized and carried out by an injection; and injectable solution that delivered directly into the lungs as a fog created using portable battery operated nebulizer devices, which enables action at infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company develops NV-HHV-1, a skin cream for the treatment of Shingles rash, which has completed non-clinical pharmacology studies; oral drug with NV-HHV-1 as the active ingredient for the treatment of HSV-1 cold sores and HSV-2 genital ulcers; and other drug candidates in HIVCide program for the treatment of Dengue and Ebola virus, as well as provides Nanoviricide platform technology to treat various types of viruses. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.
Open NNVC dashboard ↗Prestige Consumer Healthcare Inc.
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers analgesic powders under the BC and Goody's brand; various diaper rash treatments and skin protectants for babies under the Boudreaux's Butt Paste brand name; sprays and lozenges to relieve sore throats and mouth pain under the Chloraseptic brand; eye care products that provide relief from redness and itchiness under the Clear Eyes brand name; at-home removal of common and plantar warts under the Compound W brand; and ear wax removal products under Debrox brand name. The company also provides dental guards, floss picks, interdental brushes, dental repair and kits, and tongue cleaners under the DenTek brand; motion sickness relief products under the Dramamine brand; enemas and other laxative products under the Fleet brand name; stomach upset remedies under the Gaviscon brand; cough drops under the Luden's brand; products for yeast infections in women under the Monistat brand name; lice and parasite treatments under the Nix name; feminine care products, including washes, cloths, and sprays under the Summer's Eve brand; products for dry eyes under the TheraTears brand; nasal saline sprays and washes under the Fess brand name; and oral rehydration products under the Hydralyte brand. It sells its products to mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.
Open PBH dashboard ↗